MedTrace Logo

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-06-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the efficient vaccine type as a booster dose for Coronavirus Disease of 2019 (COVID-19) in solid organ transplant recipients.

Conditions

  • Covid19

Interventions

BIOLOGICAL

BNT162b2 vaccine

Single dose of 0.3 mL BNT162b2 vaccine administered intramuscularly in the deltoid muscle

BIOLOGICAL

JNJ-78436735 Vaccine

Single dose JNJ-78436735 Vaccine administered intramuscularly in the deltoid muscle

Sponsors & Collaborators

  • Giselle Guerra

    lead OTHER

Principal Investigators

  • Giselle Guerra, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-14
Primary Completion
2022-10-25
Completion
2022-10-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047640 on ClinicalTrials.gov